A PET trial to measure 5-HT2A receptor occupancy after single doses of MSP-2020 in healthy adults
Research type
Research Study
Full title
A Phase 1, Open-label, Positron Emission Tomography (PET) Trial to Measure Serotonin 5-HT2A Receptor Occupancy Following Single Oral Doses of MSP 2020 in Healthy Male Adults
IRAS ID
1012937
Contact name
Boris Reznichenko
Contact email
Sponsor organisation
Otsuka Pharmaceutical Development & Commercialization, Inc
Clinicaltrials.gov Identifier
Research summary
This is an early-stage (Phase 1) study where both researchers and participants know what treatment is being given. Up to 18 healthy men aged 23 to 55 will take part at one research center. This experimental drug, called MSP-2020, is expected to help the symptoms of depression but not cure it. By the end of the study, researchers will understand how strongly and for how long MSP-2020 attaches to its target in the brain and will to help choose the right doses for future studies. The study activities will happen at one study location that does not have any relationship with the National Health Service and one imaging location in the UK. Participants will be tested to see how the drug works in the body, how the body handles the drug, if it is safe, and how the drug changes the participant’s senses. Each participant will be in the trial for no more than 62 days. The day that the first participant signs the agreement to be in the trial will be called the Start Date. The whole study is expected to last from that Start Date until about 8 months later.
REC name
London - London Bridge Research Ethics Committee
REC reference
25/LO/0759
Date of REC Opinion
3 Dec 2025
REC opinion
Further Information Favourable Opinion